ALIMTA PD.INF. 1VIALx500MG 566 ELI-LILLY NED B.V. N ,97 963, ,66

Transcript

1 ΕΟΦ ALIMTA PD.INF. 1VIALx500MG 566 ELI-LILLY NED B.V. N ,97 963, , ANZEMET F.C.TABL 3x200MG 518 SANOFI-AVENTIS AEBE N ,53 24,82 31, ANZEMET F.C.TABL 3x50MG 518 SANOFI-AVENTIS AEBE N3816 7,95 6,92 8, ANZEMET INJ SOL BT 1AMPx100MG/5ML 518 SANOFI-AVENTIS AEBE N ,26 14,15 18, ARANESP INJ 4 PF SYRx100MCG/0,5ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,25 522,22 672, ARANESP INJ 4 PF SYRx10MCG/0,4ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,45 56,07 72, ARANESP INJ 4 PF SYRx150MCG/0,3ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,85 803, , ARANESP INJ 4 PF SYRx15MCG/0,375ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,80 78,13 100, ARANESP INJ 4 PF SYRx20MCG/0,5ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,12 107,98 139, ARANESP INJ 4 PF SYRx30MCG/0,3ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,43 164,80 212, ARANESP INJ 4 PF SYRx40MCG/0,4ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,46 208,33 268, ARANESP INJ 4 PF SYRx50MCG/0,5ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,33 260,42 335, ARANESP INJ 4 PF SYRx60MCG/0,3ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,08 321,97 414, ARANESP INJ 4 PF SYRx80MCG/0,4ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,12 432,49 557, ARANESP INJ.SOL 1PF.SYRx500MCG/1ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,36 655,42 844, ARANESP INJ.SOL. 100MCG/0,5ML PF.PEN BTx1PF.PENx0,5ML (SURE CLICK) ARANESP INJ.SOL. 150MCG/0,3ML PF.PEN BTx1PF.PENx0,3ML (SURE CLICK) ARANESP INJ.SOL. 20MCG/0,5ML PF.PEN BTx1PF.PENx0,5ML (SURE CLICK) ARANESP INJ.SOL. 300MCG/0,6ML PF.PEN BTx1PF.PENx0,6ML (SURE CLICK) ARANESP INJ.SOL. 40MCG/0,4ML PF.PEN BTx1PF.PENx0,4ML (SURE CLICK) ARANESP INJ.SOL. 500MCG/1ML PF.PEN BTx1PF.PENx1ML (SURE CLICK) ARANESP INJ.SOL. 60MCG/0,3ML PF.PEN BTx1PF.PENx0,3ML (SURE CLICK) ARANESP INJ.SOL. 80MCG/0,4ML PF.PEN BTx1PF.PENx0,4ML (SURE CLICK) 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,53 150,97 194, ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,13 217,61 280, ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,25 28,06 36, ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,72 424,32 546, ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,65 60,60 78, ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,36 655,42 844, ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,81 92,05 118, ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,41 109,98 141,67 Page 1 of 15

2 ΕΟΦ ARANESP INJ.SOL.1PF.SYRx300MCG/0,6ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,89 394,01 507, AVASTIN CS. SOL. INF 25MG/ML BTx1VIALx16ML (400MG/16ML) AVASTIN CS. SOL. INF 25MG/ML BTx1VIALx4ML (100MG/4ML) 315 ROCHE EΛΛAΣ ΑΕ N , , , ROCHE EΛΛAΣ ΑΕ N ,71 275,54 354, AVONEX INJ.SOL 4 PF SYRx30MCG/0,5ML 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,12 646,51 832, AVONEX PS.INJ.SOL 4VIALx30MCG/3ML+4PF.SYR 063 ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,52 516,36 665, BEROMUN PS.SO.INF BTx 4 VIALSx1MG+4 S0LV 214 BOEHRINGER INGELHEIM ΑΕ N , , , BETAFERON LY PD INJ 0,3 MG/VIAL BT 15 VIALS +15 PF.SYRX 2 ML SOLV BETAFERON PS.INJ.SOL 0,25MG/ML 12BTx1VIALx1PF.SYRx1,2ML SOLV+1πρ µε βελ+2τα BETAFERON PS.INJ.SOL BTx(15BTx1VIAL+1PF.SYRx1,2ML SOLV+1προσαρµ µε βελ+2ταµ CAELYX CONCENTR.INF.INJ (IV) 1FLx10MLx2MG/ML CAMPTO CS.SOL.INF 20MG/ML BTx1VIALx2ML (GLASS BOTTLE) CAMPTO CS.SOL.INF 20MG/ML BTx1VIALx5ML (GLASS BOTTLE) CAMPTO CS.SOL.INF. 20MG/ML BTx1 VIALx 15ML (PP BOTTLE) CAMPTO CS.SOL.INF. 20MG/ML BTx1 VIALx 2ML (PP BOTTLE) CAMPTO CS.SOL.INF. 20MG/ML BTx1 VIALx 5ML (PP BOTTLE) 569 BAYER SHERING PHARMA AG N ,17 593,49 764, BAYER SHERING PHARMA AG N ,32 450,07 579, BAYER SHERING PHARMA AG N ,77 644,47 830, SP.EUROPE N ,08 307,18 395, PFIZER HELLAS ΑΕ N ,80 48,55 62, PFIZER HELLAS ΑΕ N ,50 121,37 156, PFIZER HELLAS ΑΕ N ,50 364,10 469, PFIZER HELLAS ΑΕ N ,80 48,55 62, PFIZER HELLAS ΑΕ N ,50 121,37 156, CERTICAN TABL BT 60x0,25MG 321 NOVARTIS HELLAS AEΒΕ N ,73 91,12 117, CERTICAN TABL BT 60x0,50MG 321 NOVARTIS HELLAS AEΒΕ N ,30 187,31 241, CERTICAN TABL BT 60x0,75MG 321 NOVARTIS HELLAS AEΒΕ N ,02 270,59 348, CERTICAN TABL BT 60x1MG (BLIST 6x10) 321 NOVARTIS HELLAS AEΒΕ N ,82 436,58 562, CERTICAN TABL. DISP BT 60x0,25MG 321 NOVARTIS HELLAS AEΒΕ N ,73 91,12 117, COPAXONE INJ. SOL 20MG/1ML BT 28PF. SYRx1ML 431 TEVA PHARMACEUTICALS LTD N ,37 560,60 722, CYMEVENE INJ LYO. FL 12x500MG IV 315 ROCHE EΛΛAΣ ΑΕ N ,51 148,34 191, CYMEVENE LY.PD.INJ.IV FL 500 MG 315 ROCHE EΛΛAΣ ΑΕ N ,56 17,89 23,04 Page 2 of 15

3 ΕΟΦ ENBREL INJ.SOL.PF.PEN 50MG/ML BTx4 x 1ML + 8 τολύπια ENBREL NJ.SOL 25MG/0,5ML PF.SYR BTx4 PF.SYRx0,5ML + 8 τολύπια ENBREL NJ.SOL 50MG/1ML PF.SYR BTx4 PF.SYRx1ML + 8 τολύπια 489 WYETH EUROPA LTD, UK N ,52 826, , PFIZER HELLAS ΑΕ N ,98 438,46 564, PFIZER HELLAS ΑΕ N ,82 860, , ENBREL PS INJ 4 VIALSx25MG+4 SYR 295 PFIZER HELLAS ΑΕ N ,73 317,32 408, ENBREL PS. INJ.SOL 50MG VIALx PF + 4 ΒΕΛ. + 4 ΠΡΟΣΑΡΜΟΓΕΣ + 8 ΤΟΛΥΠΙΑ ENBREL PS.INJ 4VIALSx25MG+ 4P.F SYR+8NEEDLES ENBREL PS.INJ.SOL 25MG/VIAL-ΓΙΑ ΠΑΙ. ΧΡΗΣΗ BTx4VIALS+4PF.SYRX1ML SOL PFIZER HELLAS ΑΕ N ,36 657,16 846, PFIZER HELLAS ΑΕ N ,14 409,02 526, PFIZER HELLAS ΑΕ N ,23 429,98 553, EPREX INJ FL 6VIALx10000IU/ML IV 061 JANSSEN-CILAG ΑΕΒΕ N ,60 391,15 503, EPREX INJ FL 6x1000 IU/0,5ML 061 JANSSEN-CILAG ΑΕΒΕ N ,89 39,05 50, EPREX INJ FL 6x1000IU/0.5ML IV 061 JANSSEN-CILAG ΑΕΒΕ N ,89 39,05 50, EPREX INJ FL 6x2000 IU/0,5 ML IV 061 JANSSEN-CILAG ΑΕΒΕ N ,53 84,85 109, EPREX INJ FL 6X2000 IU/ML IV 061 JANSSEN-CILAG ΑΕΒΕ N ,53 84,85 109, EPREX INJ FL 6X4000 IU/ML IV 061 JANSSEN-CILAG ΑΕΒΕ N ,79 161,64 208, EPREX INJ SOL 1 VIALx40000 IU/ML 061 JANSSEN-CILAG ΑΕΒΕ N ,92 255,71 329, EPREX INJ SOL 4 VIALSx40000 IU/ML 061 JANSSEN-CILAG ΑΕΒΕ N ,69 869, , EPREX INJ SOL 6 VIALSx40000 IU/ML 061 JANSSEN-CILAG ΑΕΒΕ N , , , EPREX INJ SOL 6PF SYRx5000IU/0,5ML 061 JANSSEN-CILAG ΑΕΒΕ N ,16 205,46 264, EPREX INJ SOL 6PF SYRx6000IU/0,6ML 061 JANSSEN-CILAG ΑΕΒΕ N ,24 240,33 309, EPREX INJ SOL 6PF SYRx7000IU/0,7ML 061 JANSSEN-CILAG ΑΕΒΕ N ,38 230,88 297, EPREX INJ SOL 6PF SYRx8000IU/0,8ML 061 JANSSEN-CILAG ΑΕΒΕ N ,33 323,93 417, EPREX INJ SOL 6PF SYRx9000IU/0,9ML 061 JANSSEN-CILAG ΑΕΒΕ N ,32 296,95 382, EPREX INJ SOL 6PF.SYRx4000IU/0.4ML 061 JANSSEN-CILAG ΑΕΒΕ N ,79 161,64 208, EPREX INJ.SO.PFS IU/0,75ML PF.SYR BTx1PF.SYRx0,75ML 061 JANSSEN-CILAG ΑΕΒΕ N ,79 225,15 290,02 Page 3 of 15

4 ΕΟΦ EPREX INJ.SO.PFS IU/0,75ML PF.SYR BTx4PF.SYRx0,75ML EPREX INJ.SO.PFS IU/0,75ML PF.SYR BTx6PF.SYRx0,75ML EPREX INJ.SOL 20000IU/0,5ML PF.SYR. BTx1PF.SYRx0,5ML EPREX INJ.SOL 20000IU/0,5ML PF.SYR. BTx4PF.SYRx0,5ML EPREX INJ.SOL 20000IU/0,5ML PF.SYR. BTx6PF.SYRx0,5ML EPREX INJ.SOL 3000IV/0,3ML BT 6PF.SYR X0,3ML EPREX INJ.SOL 40000IU/1ML PF.SYR. BTx1PF.SYRx1ML EPREX INJ.SOL 40000IU/1ML PF.SYR. BTx4PF.SYRx1ML EPREX INJ.SOL 40000IU/1ML PF.SYR. BTx6PF.SYRx1ML 061 JANSSEN-CILAG ΑΕΒΕ N ,69 626,13 806, JANSSEN-CILAG ΑΕΒΕ N ,53 939, , JANSSEN-CILAG ΑΕΒΕ N ,89 140,84 181, JANSSEN-CILAG ΑΕΒΕ N ,95 438,44 564, JANSSEN-CILAG ΑΕΒΕ N ,35 845, , JANSSEN-CILAG ΑΕΒΕ N ,36 121,24 156, JANSSEN-CILAG ΑΕΒΕ N ,51 253,61 326, JANSSEN-CILAG ΑΕΒΕ N , , , JANSSEN-CILAG ΑΕΒΕ N , , , EPREX ΙΝJ FL 6x IU/ML IV 061 JANSSEN-CILAG ΑΕΒΕ N ,60 391,15 503, ETHYOL PD.SOL.INF 500MG/VIAL BTx3 VIALx500MG 636 PINNACLE BIOLOGICALS B.V. N ,08 408,10 525, FLEBOGAMMA SOL IV INF 5% 1VIALx100ML 079 DEMO AE N ,73 158,11 203, FLEBOGAMMA SOL IV INF 5% 1VIALx10ML 079 DEMO AE N ,35 15,96 20, FLEBOGAMMA SOL IV INF 5% 1VIALx200ML 079 DEMO AE N ,98 321,01 413, FLEBOGAMMA SOL IV INF 5% 1VIALx50ML 079 DEMO AE N ,22 79,36 102, GAMMAGARD SD LY.PD.INJ 1BOTTLEx5G+1BOTTLEx96ML SOLV GRANOCYTE PS.INJ.SOL 33,6MIU(263mcg)BTx5VIALS+5AMPSx1ML SOLV GRANOCYTE PS.INJ.SOL 33,6MIU(263mcg)BTxVIAL+1AMPx1ML SOLV GRANOCYTE PS.INJ.SOL.33,6MIU (263MCG)/VIAL BTx5VIALS+5PF.SYRx1ML SOLV GRANULOKINE INJ.SOL 5 PF SYRx30MU(300MCG)/0,5ML GRANULOKINE INJ.SOL 5 PF SYRx48MU(480MCG)/0,5ML GRANULOKINE INJ.SOL. 30MU(300MCG)/1ML VIAL BTx5VIALSx1ML GRANULOKINE INJ.SOL.48MU(480MCG)/1,6ML VIAL BTx5VIALSx1,6ML 034 BAXTER HELLAS ΕΠΕ N ,78 151,19 194, SANOFI-AVENTIS AEBE N ,00 294,93 379, SANOFI-AVENTIS AEBE N ,15 39,28 50, SANOFI-AVENTIS AEBE N ,00 294,93 379, AMGEN EUROPE B.V. N ,81 267,79 344, AMGEN EUROPE B.V. N ,95 440,18 567, AMGEN EUROPE B.V. N ,82 272,15 350, AMGEN EUROPE B.V. N ,95 515,87 664,50 Page 4 of 15

5 ΕΟΦ HEPSERA TABL FL 30x10MG 068 GILEAD N ,64 352,91 454, HERCEPTIN PS CO INF 1 VIALx150MG 315 ROCHE EΛΛAΣ ΑΕ N ,63 492,10 633, HUMIRA SOL.INJ. 1PF SYR 40MG/0,8ML+ALCOHOL PAD HYCAMTIN CAPS 0,25MG/CAP BTx10 σε BLIST (PVC/PCTFE/ALU) HYCAMTIN CAPS 1MG/CAP BTx10 σε BLIST (PVC/PCTFE/ALU) 512 ABBOTT LABOR. LTD N ,35 410,07 528, SMITHKLINE BEECHAM PLC N ,10 93,18 120, SMITHKLINE BEECHAM PLC N ,73 334,72 431, HYCAMTIN DR.PD.INJ 1VIALx4MG/5ML 411 GLAXO SMITHKLINΕ AEBE N ,84 158,20 203, HYCAMTIN DR.PD.INJ 5VIALx4MG/5ML IV 411 GLAXO SMITHKLINΕ AEBE N , , , INTRAGLOBIN-F SOL IV INF 5% 1AMPx10ML 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,93 20,82 26, INTRAGLOBIN-F SOL IV INF 5% 1AMPx20ML 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,59 39,66 51, INTRAGLOBIN-F SOL IV INF 5% 1ΦΙΑΛΗ ΕΚΧΥΣΗΣx100ML+SET INTRAGLOBIN-F SOL IV INF 5% 1ΦΙΑΛΗ ΕΚΧΥΣΗΣx200ML+SET INTRAGLOBIN-F SOL IV INF 5% 1ΦΙΑΛΗ ΕΚΧΥΣΗΣx50ML+SET 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,56 149,26 192, BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,94 261,82 337, BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,09 68,81 88, INTRATECT SOL.IV.INF 50MG/ML VIALx100ML 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,61 253,70 326, INTRATECT SOL.IV.INF 50MG/ML VIALx200ML 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,36 503,17 648, INTRATECT SOL.IV.INF 50MG/ML VIALx20ML 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,20 51,50 66, INTRATECT SOL.IV.INF 50MG/ML VIALx50ML 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,75 128,54 165, INTRONA INJ SOL 1VIAL x 10MIU/1ML 476 SP.EUROPE N ,52 44,82 57, INTRONA INJ SOL 1VIAL x 25MIU/2,5ML MULTIDOSE 476 SP.EUROPE N ,72 116,34 149, INTRONA INJ SOL 1VIAL x 3MIU/0,5ML 476 SP.EUROPE N ,66 11,01 14, INTRONA INJ SOL 1VIAL x 5MIU/0,5ML 476 SP.EUROPE N ,99 17,39 22, INTRONA INJ SOL 18 MIU/1,2ML PEN MULTIDOSE INTRONA INJ SOL 30 MIU/1,2ML PEN MULTIDOSE INTRONA INJ SOL 60 MIU/1,2ML PEN MULTIDOSE 476 SP.EUROPE N ,20 61,94 79, SP.EUROPE N ,81 100,75 129, SP.EUROPE N ,63 201,52 259,58 Page 5 of 15

6 ΕΟΦ INTRONA INJ SOL VIALx18MIU/3ML 476 SP.EUROPE N ,23 78,50 101, INTRONA PS INJ SOL 1MIU/VIAL + SOLV 476 SP.EUROPE N3816 4,52 3,93 5, INTRONA PS INJ SOL 30MIU/VIAL + SOLV 476 SP.EUROPE N ,81 100,75 129, KEPIVANCE PD.INJ.SOL 6,25MG/VIAL BTx6VIALS 676 BIOVINTRUM AB N , , , KINERET INJ.SOL 28PF.SYRx100MG/0,67ML 676 BIOVINTRUM AB N ,95 711,62 916, KIOVIG SOL.IV.INF 100MG/ML BTx1VIALx100ML 462 BAXTER AG N ,97 394,08 507, KIOVIG SOL.IV.INF 100MG/ML BTx1VIALx10ML 462 BAXTER AG N ,30 39,41 50, KIOVIG SOL.IV.INF 100MG/ML BTx1VIALx200ML 462 BAXTER AG N ,93 788, , KIOVIG SOL.IV.INF 100MG/ML BTx1VIALx25ML 462 BAXTER AG N ,24 98,52 126, KIOVIG SOL.IV.INF 100MG/ML BTx1VIALx50ML 462 BAXTER AG N ,48 197,04 253, LEUSTATIN INJ SO INF 10MG/10ML BT 7VIALS X 10ML LUCENTIS INJ.SOL 10MG/ML BTx1VIAL 2,3MG/0,23ML MAB CAMPATH CS.SOL.INF 30MG/ML BTx3 VIALSx1ML 061 JANSSEN-CILAG ΑΕΒΕ N , , , NOVARTIS EUROPHARM LTD N ,07 799, , GENZYME BV, NEDERLAND N ,95 931, , MAB CAMPATH CS.SOL.INF 3AMP 3MLx10MG/ML 465 GENZYME BV, NEDERLAND N ,71 844, , MABTHERA CON.SOL INF IV 1VIALx500MG/50ML 315 ROCHE EΛΛAΣ ΑΕ N , , , MABTHERA CON.SOL INF IV 2VIALx100MG/10ML 315 ROCHE EΛΛAΣ ΑΕ N ,15 423,82 545, MACUGEN SOL.INJ. 0,3MG/PF.SYR BTx1PF.SYR 90µL + προγεµισµ.συρ. χωρίς βελόνα MACUGEN SOL.INJ. 0,3MG/PF.SYR BTx1PF.SYR 90µL +εµβολο+δακτ.σταθεροποίησης MIRCERA INJ.SOL 100MCG/0,3ML PF.SYR BTx1PF.SYR MIRCERA INJ.SOL 120MCG/0,3ML PF.SYR BTx1PF.SYRx0,3ML MIRCERA INJ.SOL 150MCG/0,3ML PF.SYR BTx1PF.SYR MIRCERA INJ.SOL 200MCG/0,3ML PF.SYR BTx1PF.SYR MIRCERA INJ.SOL 250MCG/0,3ML PF.SYR BTx1PF.SYR 470 PFIZER LTD, UK N ,77 498,31 641, PFIZER LTD, UK N ,77 498,31 641, ROCHE REGISTRATION LTD,UK N ,98 173,11 222, ROCHE REGISTRATION LTD,UK N ,80 218,20 281, ROCHE REGISTRATION LTD,UK N ,39 277,87 357, ROCHE REGISTRATION LTD,UK N ,45 338,82 436, ROCHE REGISTRATION LTD,UK N ,72 414,75 534,25 Page 6 of 15

7 ΕΟΦ MIRCERA INJ.SOL 30MCG/0,3ML PF.SYR BTx1PF.SYRx0,3ML MIRCERA INJ.SOL 360MCG/0,6ML PF.SYR BTx1PF.SYRx0,6ML MIRCERA INJ.SOL 50MCG/0,3ML PF.SYR BTx1PF.SYR MIRCERA INJ.SOL 75MCG/0,3ML PF.SYR BTx1PF.SYR 487 ROCHE REGISTRATION LTD,UK N ,54 55,28 71, ROCHE REGISTRATION LTD,UK N ,02 609,89 785, ROCHE REGISTRATION LTD,UK N ,37 84,71 109, ROCHE REGISTRATION LTD,UK N ,47 122,21 157, MYFORTIC F.C. TABL BT 120x180MG 321 NOVARTIS HELLAS AEΒΕ N ,69 115,44 148, MYFORTIC F.C. TABL BT 120x360MG 321 NOVARTIS HELLAS AEΒΕ N ,02 220,13 283, MYOCET P.S.INJ.SOL.CON. 50MG 2 SET 408 WYETH EΛΛΑΣ ΑΕΒΕ N ,99 960, , NAVELBINE INJ.SOL.BT 1 VIAL X10MG/ML 291 PIERRE FABRE FARMAKA N ,57 15,29 19, NAVELBINE INJ.SOL.BT 1 VIAL X50MG/ML 291 PIERRE FABRE FARMAKA N ,05 72,25 93, NAVELBINE SOFT. CAPS BT 1x20MG 291 PIERRE FABRE FARMAKA N ,73 39,79 51, NAVELBINE SOFT. CAPS BT 1x30MG 291 PIERRE FABRE FARMAKA N ,88 59,06 76, NEORECORMON INJ SOL 6PF SYR 4000 IU x 0,3ML NEORECORMON INJ SOL 6PF SYR 6000 IU x 0,3ML NEORECORMON PS INJ SOL 1VIALx100000IU+SOLV 10ML+SYSK+SYR NEORECORMON PS INJ SOL 1VIALx50000IU+SOLV 10ML+SYSK+SYR NEORECORMON PS.INJ SOL 60000IU 1 CARTRx1ML NEORECORMON PS.INJ SOL 60000IU 3 CARTRx1ML NEORECORMON PS.INJ.SOL 10000IU 1CARTR.X1ml NEORECORMON PS.INJ.SOL 10000IU 3CARTR.X1ml NEORECORMON PS.INJ.SOL 20000IU 1CARTR.X1ml NEORECORMON PS.INJ.SOL 20000IU 3CARTR.X1ml NEORECORMON SOL INJ 1PF.SYR IUx0.6ML NEORECORMON SOL INJ 1PF.SYR. 1000IUx0.3ML 315 ROCHE EΛΛAΣ ΑΕ N ,10 171,48 220, ROCHE EΛΛAΣ ΑΕ N ,84 257,38 331, ROCHE EΛΛAΣ ΑΕ N ,30 555,32 715, ROCHE EΛΛAΣ ΑΕ N ,15 277,66 357, ROCHE EΛΛAΣ ΑΕ N ,28 343,89 442, ROCHE EΛΛAΣ ΑΕ N , , , ROCHE EΛΛAΣ ΑΕ N ,92 56,48 72, ROCHE EΛΛAΣ ΑΕ N ,58 164,93 212, ROCHE EΛΛAΣ ΑΕ N ,76 114,63 147, ROCHE EΛΛAΣ ΑΕ N ,28 343,89 442, ROCHE EΛΛAΣ ΑΕ N ,57 57,05 73, ROCHE EΛΛAΣ ΑΕ N3816 6,91 6,01 7,74 Page 7 of 15

8 ΕΟΦ NEORECORMON SOL INJ 1PF.SYR IUx0.6ML NEORECORMON SOL INJ 1PF.SYR. 2000IUx0.3ML NEORECORMON SOL INJ 1PF.SYR. 3000IUx0.3ML NEORECORMON SOL INJ 1PF.SYR. 5000IUx0.3ML 315 ROCHE EΛΛAΣ ΑΕ N ,66 111,06 143, ROCHE EΛΛAΣ ΑΕ N ,07 12,24 15, ROCHE EΛΛAΣ ΑΕ N ,33 17,69 22, ROCHE EΛΛAΣ ΑΕ N ,66 29,28 37, NEORECORMON SOL INJ 1PF.SYR. 500IUx0.3ML 315 ROCHE EΛΛAΣ ΑΕ N3816 3,39 2,95 3, NEORECORMON SOL INJ 6PF.SYR IUx0.6ML NEORECORMON SOL INJ 6PF.SYR. 1000IUx0.3ML NEORECORMON SOL INJ 6PF.SYR IUx0.6ML NEORECORMON SOL INJ 6PF.SYR. 2000IUx0.3ML NEORECORMON SOL INJ 6PF.SYR. 3000IUx0.3ML NEORECORMON SOL INJ 6PF.SYR. 5000IUx0.3ML 315 ROCHE EΛΛAΣ ΑΕ N ,35 433,56 558, ROCHE EΛΛAΣ ΑΕ N ,49 36,10 46, ROCHE EΛΛAΣ ΑΕ N ,96 666,39 858, ROCHE EΛΛAΣ ΑΕ N ,46 85,66 110, ROCHE EΛΛAΣ ΑΕ N ,76 128,55 165, ROCHE EΛΛAΣ ΑΕ N ,44 214,40 276, NEORECORMON SOL INJ 6PF.SYR. 500IUx0.3ML 315 ROCHE EΛΛAΣ ΑΕ N ,33 17,69 22, NEORECORMON SOL.INJ. 1PF.SYR 30000IUx0,6ML NEORECORMON SOL.INJ. 4PF.SYR 30000IUx0,6ML NEULASTA INJ.SOL. BT 1PF.SYR. 0,6MLx10MG/ML NEXAVAR F.C.TAB 200MG/TAB BTx112 Blist (PP/ALU) 4x ROCHE EΛΛAΣ ΑΕ N ,18 165,46 213, ROCHE EΛΛAΣ ΑΕ N ,12 841, , ΓΕΝΕΣΙΣ ΦΑΡΜΑ ΑΕ N ,43 756,40 974, BAYER HEALTH CARE AG N , , , OCTAGAM SOL IV INF 5% FL 100ML 256 ΟΚΤΑΦΑΡΜΑ N ,13 183,68 236, OCTAGAM SOL IV INF 5% FL 200ML 256 ΟΚΤΑΦΑΡΜΑ N ,38 294,39 379, OCTAGAM SOL IV INF 5% FL 20ML 256 ΟΚΤΑΦΑΡΜΑ N ,75 41,54 53, OCTAGAM SOL IV INF 5% FL 50ML 256 ΟΚΤΑΦΑΡΜΑ N ,25 77,65 100, ORENCIA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION BT 461 BRISTOL MYERS PHARMA EEIG N ,20 292,49 376,76 1VIALx250MG+1SY OVAPAC CS.SOL.INF 6MG/ML BTx1 VIAL (100MG/16,7ML) 639 ΦΑΡΜΑΤΕΝ ΕΛΛΑΣ ΑΕΒΕ N ,68 182,42 234, OVAPAC CS.SOL.INF 6MG/ML BTx1 VIAL (30MG/5ML) 639 ΦΑΡΜΑΤΕΝ ΕΛΛΑΣ ΑΕΒΕ N ,24 56,76 73,11 Page 8 of 15

9 ΕΟΦ OVAPAC CS.SOL.INF 6MG/ML BTx10 VIAL (30MG/5ML) PACLITAXEL/GENERICS CS.SOL.INF. 6MG/ML BTx 1VIALx16,7ML (100MG/16,7ML) PACLITAXEL/GENERICS CS.SOL.INF. 6MG/ML BTx 1VIALx5ML (30MG/5ML) PACLITAXEL/HOSPIRA CS.SOL.INF. BTx1VIALx16,7MLx6MG/ML PACLITAXEL/HOSPIRA CS.SOL.INF. BTx1VIALx25MLx6MG/ML PACLITAXEL/HOSPIRA CS.SOL.INF. BTx1VIALx50MLx6MG/ML PACLITAXEL/HOSPIRA CS.SOL.INF. BTx1VIALx5MLx6MG/ML PACLITOL CS.SOL.INF. BTx1VIAL 100MG/16,7ML (MULTIDOSE) PACLITOL CS.SOL.INF. BTx1VIAL 300MG/50ML (MULTIDOSE) PACLITOL CS.SOL.INF. BTx1VIAL 30MG/5ML (MONODOSE) PACLIXEL CS.SOL.INF 6MG/ML BTx1 VIAL (100MG)X16,7ML PACLIXEL CS.SOL.INF 6MG/ML BTx1 VIAL (30MG)X5ML PATAXEL BTx1VIAL (100MG) x 16,7ML (MULTIDOSE) PATAXEL BTx1VIAL (300MG) x 50ML (MULTIDOSE) 639 ΦΑΡΜΑΤΕΝ ΕΛΛΑΣ ΑΕΒΕ N ,45 567,63 731, GENERICS PHAR.HELLAS ΕΠΕ N ,68 182,42 234, GENERICS PHAR.HELLAS ΕΠΕ N ,24 56,76 73, HOSPIRA UK LTD N ,68 182,42 234, HOSPIRA UK LTD N ,24 283,83 365, HOSPIRA UK LTD N ,25 527,44 679, HOSPIRA UK LTD N ,24 56,76 73, ΦΑΡΜΑΝΕΛ ΦΑΡΜ/ΚΗ ΑΕ N ,68 182,42 234, ΦΑΡΜΑΝΕΛ ΦΑΡΜ/ΚΗ ΑΕ N ,25 527,44 679, ΦΑΡΜΑΝΕΛ ΦΑΡΜ/ΚΗ ΑΕ N ,24 56,76 73, NOVAGEN PHARMACEUTICALS N ,68 182,42 234, NOVAGEN PHARMACEUTICALS N ,24 56,76 73, BIANEΞ AE N ,68 182,42 234, BIANEΞ AE N ,25 527,44 679, PATAXEL BTx1VIAL (30MG) x 5ML (MONODOSE) 040 BIANEΞ AE N ,24 56,76 73, PAXENE CS.SOL.NF 1VIAL 17MLx6MG/ML 060 ΓEPOΛYMATOΣ Π.N ΑΕΒΕ N ,68 182,42 234, PAXENE CS.SOL.NF 1VIAL 50MLx6MG/ML 060 ΓEPOΛYMATOΣ Π.N ΑΕΒΕ N ,25 527,44 679, PAXENE PACLITAXEL CS.SOL.INF 6MG/ML BTx1VIALx25ML PAXENE PACLITAXEL CS.SOL.INF. 6MG/ML BTx1VIALx16,7ML PAXENE PACLITAXEL CS.SOL.INF. 6MG/ML BTx1VIALx50ML PAXENE PACLITAXEL CS.SOL.INF. 6MG/ML BTx1VIALx5ML 608 PHARMACHEMIE B.V. HOLLAND N ,24 283,83 365, PHARMACHEMIE B.V. HOLLAND N ,68 182,42 234, PHARMACHEMIE B.V. HOLLAND N ,25 527,44 679, PHARMACHEMIE B.V. HOLLAND N ,24 56,76 73, PEGASΥS INJ.SOL.PF.SYR 1x135MCG/0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,82 125,99 162, PEGASΥS INJ.SOL.PF.SYR 1x180MCG/0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,82 146,00 188,07 Page 9 of 15

10 ΕΟΦ PEGASΥS INJ.SOL.PF.SYR 4x135MCG/0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,32 494,44 636, PEGASΥS INJ.SOL.PF.SYR 4x180MCG/0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,73 573,10 738, PEGINTRON PS INJ PREFILL PEN 100MCG 476 SP.EUROPE N ,80 144,25 185, PEGINTRON PS INJ PREFILL PEN 120MCG 476 SP.EUROPE N ,94 173,08 222, PEGINTRON PS INJ PREFILL PEN 150MCG 476 SP.EUROPE N ,52 220,56 284, PEGINTRON PS INJ PREFILL PEN 50MCG 476 SP.EUROPE N ,91 72,13 92, PEGINTRON PS INJ PREFILL PEN 80MCG 476 SP.EUROPE N ,10 114,93 148, PEGINTRON PS INJ SOL 1 VIALx100MCG+SOLV 0,5ML PEGINTRON PS INJ SOL 1 VIALx120MCG+SOLV 0,5ML PEGINTRON PS INJ SOL 1 VIALx150MCG+SOLV 0,5ML PEGINTRON PS INJ SOL 1 VIALx80MCG+SOLV 0,5ML 476 SP.EUROPE N ,80 144,25 185, SP.EUROPE N ,33 137,75 177, SP.EUROPE N ,10 208,89 269, SP.EUROPE N ,48 91,77 118, PEGINTRON PS INJ SOL 1VIALx50MCG+SOLV 476 SP.EUROPE N ,78 58,97 75, PENTAGLOBIN SOL.IV.INF 50MG/ML 1AMPx10ML 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,89 36,44 46, PENTAGLOBIN SOL.IV.INF 50MG/ML 1AMPx20ML 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,86 68,61 88, PENTAGLOBIN SOL.IV.INF 50MG/ML 1BOTTLEx100ML PENTAGLOBIN SOL.IV.INF 50MG/ML 1BOTTLEx50ML PROGRAF CAPS 30(BLIST 3x10 SACHETS AL)x1MG PROGRAF CAPS 30(BLIST 3x10 SACHETS AL)x5MG 212 BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,00 296,67 382, BIOTEST ΕΛΛΑΣ Μ.Ε.Π.Ε. N ,40 149,99 193, ASTELLAS PHARM/CALS AEBE N ,52 43,08 55, ASTELLAS PHARM/CALS AEBE N ,09 205,40 264, PROGRAF CAPS BT 30x0,5MG 440 ASTELLAS PHARM/CALS AEBE N ,56 23,11 29, PROGRAF CS.SOL.INF 10AMPx5MG/1ML 440 ASTELLAS PHARM/CALS AEBE N ,18 331,63 427, RAPAMUNE F.C.TABL BT 30x1MG 295 PFIZER HELLAS ΑΕ N ,35 97,74 125, RAPAMUNE ORAL SOL FL 150MLx1MG/ML 408 WYETH EΛΛΑΣ ΑΕΒΕ N ,96 364,50 469, RAPAMUNE ORAL SOL FL 60MLx1MG/ML 295 PFIZER HELLAS ΑΕ N ,58 145,79 187,79 Page 10 of 15

11 ΕΟΦ RAPAMUNE SACHETS 30x1MG/ML 408 WYETH EΛΛΑΣ ΑΕΒΕ N ,79 72,90 93, RAPAMUNE SACHETS 30x2MG/2ML 408 WYETH EΛΛΑΣ ΑΕΒΕ N ,58 145,79 187, RAPAMUNE SACHETS 30x5MG/5ML 408 WYETH EΛΛΑΣ ΑΕΒΕ N ,96 364,50 469, REBIF INJ.SOL 132MCG (44MCG/0,5ML)/1,5ML BTx4 CARTRIDGES REBIF INJ.SOL 66MCG (22MCG/0,5ML)/1,5ML BTx4 CARTRIDGES 483 SERONO (EUROPE) LTD UK N ,04 808, , SERONO (EUROPE) LTD UK N ,49 699,91 901, REBIF-22MCG(6MIU) INJ SOL 12PF.SYRx0.5ML 326 SERONO HELLAS ΑΕ N ,77 670,57 863, REBIF-22MCG(6MIU) INJ SOL 1PF.SYRx0.5ML 326 SERONO HELLAS ΑΕ N ,53 43,96 56, REBIF-22MCG(6MIU) INJ SOL 3PF.SYRx0.5ML 326 SERONO HELLAS ΑΕ N ,63 167,59 215, REBIF-44 MCG(12 MIU) INJ SOL 1 PF SYRx1ML 326 SERONO HELLAS ΑΕ N ,32 59,44 76, REBIF-44 MCG(12 MIU) INJ SOL 12 PF SYRx1ML 326 SERONO HELLAS ΑΕ N ,32 769,36 991, REBIF-44 MCG(12 MIU) INJ SOL 3 PF SYRx1ML 326 SERONO HELLAS ΑΕ N ,12 192,37 247, REMICADE PD.SOL.INF 1FLx100MG/20ML 109 SCHERING PLOUGH AΦBEE N ,71 459,98 592, REMODULIN SOL.INF 10MG/ML BTx1VIALx20ML 442 FERRER-GALENICA A.E. N , , , REMODULIN SOL.INF 1MG/ML BTx1VIALx20ML 442 FERRER-GALENICA A.E. N , , , REMODULIN SOL.INF 2,5MG/ML BTx1VIALx20ML 442 FERRER-GALENICA A.E. N , , , REMODULIN SOL.INF 5MG/ML BTx1VIALx20ML 442 FERRER-GALENICA A.E. N , , , RETACRIT INJ.SOL IU/1,0ML PF.SYR BTx6 PF.SYRSx1,0ML RETACRIT INJ.SOL. 1000IU/0,3ML PF.SYR BTx6 PF.SYRSx0,3ML RETACRIT INJ.SOL. 2000IU/0,6ML PF.SYR BTx6 PF.SYRSx0,6ML RETACRIT INJ.SOL. 3000IU/0,9ML PF.SYR BTx6 PF.SYRSx0,9ML RETACRIT INJ.SOL IU/1,0ML PF.SYR BTx1 PF.SYRx1,0ML RETACRIT INJ.SOL IU/1,0ML PF.SYR BTx4 PF.SYRSx1,0ML RETACRIT INJ.SOL. 4000IU/0,4ML PF.SYR BTx6 PF.SYRSx0,4ML 654 HOSPIRA UK LTD N ,71 328,61 423, HOSPIRA UK LTD N ,34 35,97 46, HOSPIRA UK LTD N ,69 66,72 85, HOSPIRA UK LTD N ,05 100,09 128, HOSPIRA UK LTD N ,11 256,75 330, HOSPIRA UK LTD N , , , HOSPIRA UK LTD N ,41 133,47 171,93 Page 11 of 15

12 ΕΟΦ RETACRIT INJ.SOL. 5000IU/0,5ML PF.SYR BTx6 PF.SYRSx0,5ML RETACRIT INJ.SOL. 6000IU/0,6ML PF.SYR BTx6 PF.SYRSx0,6ML RETACRIT INJ.SOL. 8000IU/0,8ML PF.SYR BTx6 PF.SYRSx0,8ML 654 HOSPIRA UK LTD N ,74 166,81 214, HOSPIRA UK LTD N ,10 200,19 257, HOSPIRA UK LTD N ,14 279,39 359, REVATIO F.C. TABL 20MG/TAB BTx PFIZER LTD, UK N ,14 396,84 511, REVLIMID HARD CAPS 10MG/CAP BTx21 σε BLISTERS (PCTFE/PVC/ALU) REVLIMID HARD CAPS 15MG/CAP BTx21 σε BLISTERS (PCTFE/PVC/ALU) REVLIMID HARD CAPS 25MG/CAP BTx21 σε BLISTERS (PCTFE/PVC/ALU) REVLIMID HARD CAPS 5MG/CAP BTx21 σε BLISTERS (PCTFE/PVC/ALU) 567 CELGENE EUROPE LTD N , , , CELGENE EUROPE LTD N , , , CELGENE EUROPE LTD N , , , CELGENE EUROPE LTD N , , , RILUTEK F.C.TABL 56x50MG 316 AVENTIS PHARMA ΑΒΕE N ,23 182,90 235, ROFERON-A INJ SOL 3MIU 1PF.SYR.x0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,18 13,21 17, ROFERON-A INJ SOL 3MIU 6PF.SYR.x0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,12 79,27 102, ROFERON-A INJ SOL 4.5MIU 1PF.SYR.x0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,41 18,63 24, ROFERON-A INJ SOL 4.5MIU 6PF.SYR.x0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,45 111,75 143, ROFERON-A INJ SOL 6MIU 1PF.SYR.x0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,04 24,39 31, ROFERON-A INJ SOL 6MIU 6PF.SYR.x0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,57 163,19 210, ROFERON-A INJ SOL 9MIU 1PF.SYR.x0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,12 38,38 49, ROFERON-A INJ SOL 9MIU 6PF.SYR.x0,5ML 315 ROCHE EΛΛAΣ ΑΕ N ,47 167,45 215, SANDOGLOBULIN INJ LYOPH FL 6GR+SOLV 200ML IV SANDOGLOBULIN INJ LYOPH. FL 3GR+SOLV 100ML IV SANDOSTATIN LAR PS.INJ.SUS 10MG/VIAL BTx1VIAL +1PF.SYRx2,5ML SOLV+2 βελόνες SANDOSTATIN LAR PS.INJ.SUS 20MG/VIAL BTx1VIAL +1PF.SYRx2,5ML SOLV+2 βελόνες SANDOSTATIN LAR PS.INJ.SUS 30MG/VIAL BTx1VIAL +1PF.SYRx2,5ML SOLV+2 βελόνες 438 CSL BEHRING Μ.ΕΠΕ N ,63 195,43 251, CSL BEHRING Μ.ΕΠΕ N ,72 98,07 126, NOVARTIS HELLAS AEΒΕ N ,21 465,63 599, NOVARTIS HELLAS AEΒΕ N ,12 744,82 959, NOVARTIS HELLAS AEΒΕ N ,80 966, , SIMULECT PS.INJ.SOL 1VIALx20MG+1SYR SOLV 321 NOVARTIS HELLAS AEΒΕ N ,87 858, ,95 Page 12 of 15

13 ΕΟΦ SPRYCEL F.C. TABS 60x20MG (BLISTER) 461 BRISTOL MYERS PHARMA EEIG N , , , SPRYCEL F.C. TABS 60x20MG (BOTTLE) 461 BRISTOL MYERS PHARMA EEIG N , , , SPRYCEL F.C. TABS 60x50MG (BLISTER) 461 BRISTOL MYERS PHARMA EEIG N , , , SPRYCEL F.C. TABS 60x50MG (BOTTLE) 461 BRISTOL MYERS PHARMA EEIG N , , , SPRYCEL F.C. TABS 60x70MG (BLISTER) 461 BRISTOL MYERS PHARMA EEIG N , , , SPRYCEL F.C. TABS 60x70MG (BOTTLE) 461 BRISTOL MYERS PHARMA EEIG N , , , SUBCUVIA INJ.SOL. 160MG/ML BTx1VIALx10ML 462 BAXTER AG N ,66 57,12 73, SUBCUVIA INJ.SOL. 160MG/ML BTx1VIALx5ML 462 BAXTER AG N ,84 28,57 36, SUBCUVIA INJ.SOL. 160MG/ML BTx20VIALSx5ML 462 BAXTER AG N ,65 571,29 735, SUBCUVIA INJ.SOL. 160MG/ML BTx20VIALx10ML 462 BAXTER AG N , , , SUTENT CAPS 12,5MG/CAP BOTTLEx30CAPS 470 PFIZER LTD, UK N ,44 986, , SUTENT CAPS 25MG/CAP BOTTLEx30CAPS 470 PFIZER LTD, UK N , , , SUTENT CAPS 50MG/CAP BOTTLEx30CAPS 470 PFIZER LTD, UK N , , , TARCEVA F.C. TABS BT 30x100MG 315 ROCHE EΛΛAΣ ΑΕ N , , , TARCEVA F.C. TABS BT 30x150MG 315 ROCHE EΛΛAΣ ΑΕ N , , , TARCEVA F.C. TABS BT 30x25MG 315 ROCHE EΛΛAΣ ΑΕ N ,32 287,38 370, TASIGNA HARD.CAPS 200MG/TAB BTx112TABS σε BLISTERS (PVC/OPA/ALU) TAXOL CS. SOL. INF.(Concentrate) 6MG/ML BTx1 VIAL MULTIDOSE (300MG)x50ML TAXOL CS. SOL. INF.(Concentrate) 6MG/ML BTx1(VIALx25MLx150MG) TAXOL CS.SOL.INF (CONCENTRATE) 6MG/ML BTx1VIAL 30MG/5ML TAXOL CS.SOL.INF (CONCENTRATE) 6MG/ML BTx1VIAL MULTIDOSE 100MG/17ML TAXOPROL CS.SOL.INF. BTx1VIAL(100MG)X16,7ML (MULTIDOSE) TAXOPROL CS.SOL.INF. BTx1VIAL(30MG)X5ML (MONODOSE) 517 NOVARTIS EUROPHARM LTD N , , , BRISTOL-MYERS SQUIBB AE N ,61 586,04 754, BRISTOL-MYERS SQUIBB AE N ,49 315,37 406, BRISTOL-MYERS SQUIBB AE N ,49 63,07 81, BRISTOL-MYERS SQUIBB AE N ,98 202,69 261, NOVENDIA PHARMACEUTICALS ΕΠΕ NOVENDIA PHARMACEUTICALS ΕΠΕ Page 13 of 15 N ,68 182,42 234,98 N ,24 56,76 73,11

14 ΕΟΦ TAXOTERE 80MG/2,0ML/1VIAL 316 AVENTIS PHARMA ΑΒΕE N ,66 462,54 595, TAXOTERE INJ CO INF 1VIALx20MG/0,5ML 316 AVENTIS PHARMA ΑΒΕE N ,89 119,09 153, TEMODAL CAPS 20x20MG 476 SP.EUROPE N ,13 229,79 296, TEMODAL CAPS 20x5MG 476 SP.EUROPE N ,16 61,04 78, TEMODAL CAPS 5x100MG 476 SP.EUROPE N ,11 323,74 417, TEMODAL CAPS 5x20MG 476 SP.EUROPE N ,03 65,28 84, TEMODAL CAPS 5x250MG 476 SP.EUROPE N ,67 816, , TEMODAL CAPS 5x5MG 476 SP.EUROPE N ,93 17,34 22, TEMODAL HARD CAPS 140MG/CAP BOTTLEx20 CAPS TEMODAL HARD CAPS 140MG/CAP BOTTLEx5 CAPS TEMODAL HARD CAPS 180MG/CAP BOTTLEx5 CAPS 476 SP.EUROPE N , , , SP.EUROPE N ,57 476,39 613, SP.EUROPE N ,89 609,77 785, TEMODAL PD.SOL.INF 2,5MG/ML BTx1BOTTLE 476 SP.EUROPE N ,01 256,66 330, THELIN F.C. TAB 100MG/TAB BTx28 BLISTERS (PVC/PE/PVDC/ALU) 295 PFIZER HELLAS ΑΕ N , , , TORISEL C.DI.S.INF 25MG/ML BTx1VIAL +1VIAL 295 PFIZER HELLAS ΑΕ N ,43 819, , TRACLEER F.C.TAB BT 56x125MG 020 ACTELION N , , , TRACLEER F.C.TAB BT 56x62,5MG 020 ACTELION N , , , TRISENOX CS.SOL.INF 1MG/ML BTx10AMPSx10ML TYSABRI CS. SOL.INF 300MG/15ML VIAL BTx1VIALx15ML TYVERB FC. TAB 250MG/TAB BTx70 σε BLISTERS (PA/ALU/PVC/ALU) VECTIBIX CS.SOL.INF 100MG/5ML VIAL (20MG/ML) BTx1VIALx5ML VECTIBIX CS.SOL.INF 400MG/20ML VIAL (20MG/ML) BTx1VIALx20ML 142 CEPHALON UK LTD N , , , ELAN N , , , GLAXO GROUP LTD, ENGLAND N ,16 882, , AMGEN EUROPE B.V. N ,96 351,45 452, AMGEN EUROPE B.V. N , , , VELCADE PS.INJ.SOL 1VIALx3,5MG 061 JANSSEN-CILAG ΑΕΒΕ N ,09 877, , VENTAVIS INH.SOL AMP 100x20MCG/2ML 569 BAYER SHERING PHARMA AG N , , ,70 Page 14 of 15

15 ΕΟΦ VENTAVIS INH.SOL BTx90AMPSx2ML 569 BAYER SHERING PHARMA AG N , , , VIVAGLOBIN INJ.SOL.16% BTx10AMPx5ML 438 CSL BEHRING Μ.ΕΠΕ N ,70 258,13 332, VIVAGLOBIN INJ.SOL.16% BTx10VIALSx10ML 438 CSL BEHRING Μ.ΕΠΕ N ,59 498,15 641, VIVAGLOBIN INJ.SOL.16% BTx1AMPx5ML 438 CSL BEHRING Μ.ΕΠΕ N ,67 25,81 33, VIVAGLOBIN INJ.SOL.16% BTx1VIALx10ML 438 CSL BEHRING Μ.ΕΠΕ N ,26 49,82 64, VIVAGLOBIN INJ.SOL.16% BTx20VIALSx10ML 438 CSL BEHRING Μ.ΕΠΕ N ,60 998, , VOLIBRIS F.C.TAB 10MG/TAB BTx30 σε BLIST (PVC/PVDC/ALU) VOLIBRIS F.C.TAB 5MG/TAB BTx30 σε BLIST (PVC/PVDC/ALU) YONDELIS PD.C.SOL.INF. 0,25MG/VIAL BTx1 VIAL 491 GLAXO GROUP LTD, ENGLAND N , , , GLAXO GROUP LTD, ENGLAND N , , , PHARMA MAR, S.A. N ,68 465,17 599, YONDELIS PD.C.SOL.INF. 1MG/VIAL BTx1 VIAL 603 PHARMA MAR, S.A. N , , , ZAVESCA HARD CAPS BT 84x100MG 020 ACTELION N , , ,01 Page 15 of 15